Leftover stocks of high-priced medicines are emerging as a serious headache for Japanese pharmacies, fueling financial stress and even bankruptcies…
ORGANIZATION
3 Indicted Wholesalers Barred from JCHO Bids for 2 Years: Bid-Rigging Scandal
The Japan Community Healthcare Organization (JCHO) has barred three major wholesalers indicted on December 9 over bid-rigging charges from participating its future bids for drug procurement for two years. The JCHO said in a press release dated December 10 that…
To read the full story
Related Article
- Mediceo Gets 6-Month Suspension from National Hospital Organization Bids
April 18, 2022
- Mediceo Dodged Charges and FTC Penalties, but Still Barred from JCHO Bids
April 12, 2022
- 3 Wholesalers Ordered to Pay 420 Million Yen in Surcharge over Bid-Rigging; JCHO to Suspend Mediceo Too
March 31, 2022
- Guilty Rulings for 3 Wholesalers, Employees Now Final and Binding: Bid-Rigging Trial
July 19, 2021
- 3 Major Wholesalers, 7 Employees Found Guilty in Bid-Rigging Trial
July 2, 2021
- 300 Million Yen Fine Sought for Alfresa Too, Verdict on June 30: Bid-Rigging Trial
May 13, 2021
- 300 Million Yen Fine Sought for Toho Too, Court Decision Due June 2: Bid-Rigging Trial
April 30, 2021
- Prosecutors Seek 300 Million Yen Fine for Suzuken, Jail Terms for Employees: Bid-Rigging Trial
April 28, 2021
- 3 Indicted Wholesalers Barred from JCHO/NHO Bids, but Can Sell Single-Channel Drugs to Ensure Access
January 26, 2021
- 3 Indicted Wholesalers Now Barred from National Hospital Organization Bids, Others Following Suit
December 21, 2020
- (Update) Criminal Charges Sought against 3 Wholesalers over Bid-Rigging, Mediceo Excluded
December 10, 2020
- Criminal Charges Sought against 3 Wholesalers over Bid-Rigging, Mediceo Excluded
December 9, 2020
- JPWA Raided Too over Big 4 Wholesalers’ Bid-Rigging Scandal
October 16, 2020
- Big 4 Wholesalers Now Suspected to Have Rigged Drug Prices in 2016 Too
October 14, 2020
- Big 4 Wholesalers Raided Again over Suspected Bid-Rigging
October 13, 2020
- JCHO Hospitals to Switch from Joint to Separate Bidding for Drug Purchases after Bid-Rigging Scandal
May 21, 2020
- “Tender Process Needs to Be Improved” in Response to Bid-Rigging Scandal by Top 4 Wholesalers: Hospital Management Advisor
February 25, 2020
- MHLW Bureau Chief Says Delay Would Be Inevitable to Revise Drug Distribution Guidelines as Bid-Rigging Probe Continues
January 17, 2020
- Big 4 Wholesalers Faced Wrath of FTC for Allocating Priority Drug Categories before Bidding
December 6, 2019
- Wholesalers’ Bid-Rigging Scandal Might Have Been Exposed via Leniency Program, Further Cases Could Be Laid Bare: Lawyer
December 6, 2019
- Scandal-Hit JPWA Likely to Pass on Chuikyo’s Industry Hearing on Dec. 6
December 4, 2019
- Ryukaikon’s Dec. 9 Meeting Likely to Be Put Off in Wake of Bid-Rigging Scandal
December 3, 2019
- Stakeholders Rap Big 4 Wholesalers for Bid-Rigging Charges, Say Scandal Shutters Trust in Drug Price Surveys
November 29, 2019
- Big 4 Drug Wholesalers Raided on Bid-Rigging Charges
November 28, 2019
ORGANIZATION
- JPMA Regulatory Chief Seeks Balanced Approach on Japanese PI Waivers
September 3, 2025
- Clinical Trial Environment Must Match Global Standards, Says JPMA Evaluation Chief
September 2, 2025
- Information Provisioning on Solo Channels Is Duty of Both Makers and Wholesalers: JPMA Distribution Chief
September 1, 2025
- Indicators Needed to Frame Pharma as Growth Market in Japan, Says JPMA Policy Chief
August 29, 2025
- Wage Hikes Average in Low 4% Range, Similar to Last Year: Pharma Labor Group
August 28, 2025
A recent conversation with a US biopharma senior director highlighted a critical talent gap: a strong demand for individuals with strategic management, critical thinking, and advanced business acumen-skills beyond traditional operational excellence. After the conversation, I rushed home and picked…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…